Home›Research›Compare›BPC-157 vs NAD+
Peptide ComparisonBPC-157 vs NAD+
BPC-157
Body Protection Compound 157
Half-life: Under 30 minutes (plasma); no human PK data
635 providers listed
NAD+
NAD
Half-life: ~1–2 hours (IV); variable (oral)
447 providers listed
BPC-157 and NAD+ target different goals — BPC-157 for tissue repair across tendon, muscle, nerve, and gut — most broadly studied recovery peptide, NAD+ for NAD+/NADH ratio restoration supporting cellular energy production. They're compared here for reference, not as direct substitutes.
BPC-157
Evidence
Half-life
Under 30 minutes (plasma); no human PK data
NAD+
Evidence
Half-life
~1–2 hours (IV); variable (oral)
BPC-157 and NAD+ target different goals — BPC-157 for Tissue Repair, NAD+ for Longevity & Cellular. They're compared here for reference; there isn't a single “better” choice between them.
BPC-157
NAD+
BPC-157
Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery.
Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury.
BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and…
Unilateral Adrenalectomy, and the Stable Pentadecapeptide BPC 157 as Therapy in Rats-A Cytoprotection Approac…
+6 more
NAD+
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and…
Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence
Extracellular Lactate Reprograms Mitochondrial Metabolism and NAD(+)/NADH Redox Balance in Blood-Brain Barrie…
+4 more
About BPC-157
BPC-157 is believed to accelerate angiogenesis and upregulate growth hormone receptors locally at injury sites. It appears to promote fibroblast migration and collagen synthesis, contributing to faster tissue remodelling. Animal studies suggest systemic effects via modulation of the dopaminergic and serotonergic systems, though human data remain limited.
About NAD+
NAD+ is a coenzyme central to cellular energy metabolism, serving as an electron carrier in glycolysis, the citric acid cycle, and oxidative phosphorylation. It is also a required substrate for sirtuins (SIRT1–7) and PARP enzymes, which regulate DNA repair, gene expression, and mitochondrial biogenesis. NAD+ levels decline measurably with age; IV or subcutaneous delivery aims to restore intracellular pools more directly than oral precursors such as NMN or NR.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
BPC-157
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
global — WADA
BPC-157 is on the WADA Prohibited List at all times (S0, Non-Approved Substances), effective 1 January 2022. It has no FDA approval and no adequate human clinical trial.
sourceNAD+
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
BPC-157
GHK-Cu
Research suggests GHK-Cu and BPC-157 may produce complementary tissue repair and anti-inflammatory effects when combined. GHK-Cu is studied for copper-dependent collagen synthesis and antioxidant gene activation, while BPC-157 supports angiogenesis and growth factor expression.
TB-500
Research suggests BPC-157 and TB-500 may produce enhanced tissue repair effects when combined. BPC-157 is studied for angiogenesis and gut-protective properties, while TB-500 promotes actin assembly and cell migration — complementary mechanisms in healing models.
Anticoagulants / blood thinners
Research notes that BPC-157 promotes angiogenesis and may influence platelet and vascular function in healing models. Combined use with anticoagulant medications may warrant monitoring. Consult your prescriber before combining.
BPC-157
NAD+
Where to source these peptides
BPC-157
635 listed
Browse directory →
Providers offeringNAD+
447 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
Related Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 20, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). BPC-157 vs NAD+ — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/bpc-157/nad-plus